Could adding erlotinib to chemo shrink head and neck tumors better?
NCT ID NCT01927744
First seen Jan 09, 2026 · Last updated Apr 24, 2026 · Updated 17 times
Summary
This study looked at whether adding the targeted drug erlotinib to standard chemotherapy (docetaxel plus cisplatin or carboplatin) helps shrink head and neck tumors more than chemo alone before surgery. About 55 adults with advanced but operable head and neck cancer took part. The main goal was to see how many patients had very few cancer cells left in the removed tumor after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.